← Plastic & Cosmetic Surgery Anesthesia

GLP-1 Medications and Anesthesia Risk: What Cosmetic Surgeons Need to Screen For

A 41-year-old patient arrives for an abdominoplasty and breast lift. She is healthy, motivated, and has lost 60 pounds in the past year — which is why she is in your office. What her intake form does not say, because no one asked the question in a way she understood, is that she took her weekly tirzepatide injection two days ago. She followed her NPO instructions to the letter. Her stomach is not empty anyway.

This is now one of the most common preventable disruptions in aesthetic surgery. GLP-1 receptor agonists delay gastric emptying by design — that is the mechanism that produces satiety and weight loss. The same mechanism means a patient can be twelve hours NPO and still have solid gastric contents at induction. For a practice whose patients are cash-pay, whose OR block is fixed, and whose surgical volume increasingly comes from GLP-1 weight loss, this is both a safety problem and a business problem.

Why the Aesthetic Patient Population Is the Epicenter

No specialty is more exposed to this than plastic and cosmetic surgery. GLP-1 medications have created an entire referral stream — patients who lose substantial weight and then present for the body contouring, brachioplasty, mastopexy, and facial volume restoration that follows. Many are still on the drug when they reach your OR. Others stopped weeks ago but resumed for maintenance. A meaningful number are taking compounded semaglutide obtained outside a physician relationship and do not consider it “a medication” when filling out your history form.

Compounding the exposure: liposuction has been the most-performed surgical cosmetic procedure in the United States for two consecutive years, and breast augmentation volume rose 11% in the most recent ASPS reporting period.¹ The procedures growing fastest are precisely the ones this patient population seeks.

What the Guidance Actually Says in 2026

The advice has changed, and practices operating on the 2023 version are creating unnecessary cancellations.

The June 2023 ASA consensus statement took a conservative, uniform position: hold daily-dosed GLP-1 agonists on the day of the procedure, and hold weekly-dosed agents for one week prior.³ It was a reasonable first response to a new signal, but it was blunt — it interrupted therapy for every patient regardless of risk, and it produced a wave of last-minute cancellations when patients disclosed their medication too late to hold it.

The October 2024 multisociety clinical practice guidance — developed jointly by the American Society of Anesthesiologists, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — replaced the blanket hold with risk stratification and shared decision-making.² Its authors are explicit that the document is guidance, not an evidence-based guideline, and that the goal is balancing safety processes with therapeutic metabolic need.² In practice, the framework does three things a cosmetic practice should understand:

• It stratifies rather than prohibits. Patients are assessed for elevated residual-gastric-content risk based on factors such as dose escalation phase, GI symptoms, and the nature of the procedure — rather than every GLP-1 user being handled identically.
• It offers a liquid-diet pathway. A clear liquid diet for 24 hours before the procedure is presented as a risk-mitigation option that does not require interrupting therapy — the single most useful change for elective aesthetic scheduling.
• It puts the decision on the day-of assessment. Where risk remains uncertain, gastric ultrasound can inform whether to proceed, and where a full stomach must be assumed, the case proceeds with aspiration precautions and an airway plan built for it.

The honest framing for surgeons: absolute aspiration events under anesthesia remain rare, and much of the published evidence documents increased residual gastric contents rather than a proportional epidemic of aspiration pneumonitis. That is not a reason to relax. It is a reason to treat this as a screening and preparation problem — which is entirely solvable — rather than a reason to turn patients away.

The Cancellation Math Is Different in Cash-Pay Surgery

In an insurance-based OR, a day-of cancellation is a scheduling failure. In aesthetic surgery it is a customer-service failure with a refund attached.

Your patient took a week off work. She arranged childcare and a caregiver for the first 48 hours. She paid a deposit, in many cases the full fee, months ago. She has told friends. When she is sent home at 7:15 a.m. because no one asked about her injection in time, the practice absorbs an empty room with fully staffed labor and fixed overhead, a rebooking that displaces future capacity, a refund conversation, and a real risk that the review she leaves has nothing to do with your surgical result. For a two-room aesthetic OR, a lost morning routinely represents five figures of combined facility, surgeon, and anesthesia revenue — and unlike a covered procedure, there is no payer backstop for any of it.

Every one of those consequences is preventable at the point of screening.

What a Working Screening Protocol Looks Like

The failure is almost never clinical judgment on the day. It is that the information arrived too late to act on. A protocol that actually prevents cancellations has these properties:

• It asks by brand name, not by drug class. “Are you taking any GLP-1 medications?” gets fewer disclosures than “Are you taking Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, semaglutide, or tirzepatide — including compounded or telehealth-prescribed versions?”
• It asks early enough to matter. Screening days ahead — not at the pre-op visit and certainly not on the morning of surgery — is what preserves the option to adjust dosing or assign a 24-hour clear liquid diet.
• It captures dose, last dose date, and titration status, because a patient escalating her dose and a patient stable on maintenance are not the same risk.
• It routes the answer to the anesthesia provider, not into a chart field no one reads until induction.
• It pairs with written patient instructions that explain the liquid-diet window in language a layperson will follow, since the intervention only works if the patient complies with it.

The same screening pass should be catching the rest of the picture in this population — significant weight loss history, nutritional status, cardiac risk, airway assessment, and the other factors that decide whether a long combination case is appropriate in an office OR at all, a question we take up in Long Combination Cases.

How Illume Handles It

Illume Anesthesia’s pre-screening protocol evaluates more than 200 clinical risk factors days before the day of surgery, and GLP-1 exposure is a named element of it — asked by brand, captured with dose and timing, and reviewed by the anesthesia provider who will actually be in your room. When a patient’s risk profile warrants it, we assign the clear-liquid pathway and the patient receives instructions early enough to follow them. When it warrants full-stomach precautions, we arrive with that plan already made and the airway approach settled.

The result our aesthetic practices care about is not the protocol. It is that the schedule holds: patients arrive optimized, cleared, and ready, and the morning-of conversation about a medication nobody asked about does not happen. That reliability is the same discipline that produces the smooth emergence and low PONV rates covered in PONV and the Aesthetic Patient Experience.

Explore Our Plastic & Cosmetic Surgery Anesthesia Services